Price Alert

MannKind Corporation (MNKD)

NASDAQ: MNKD · Real-Time Price · USD

3.71

0.01 (0.27%)

At close: Aug 15, 2025, 10:02 AM

0.27% (1D)

Bid	3.71
Market Cap	1.14B
Revenue (ttm)	297.6M
Net Income (ttm)	30.12M
EPS (ttm)	0.11
PE Ratio (ttm)	33.77
Forward PE	20.68
Analyst	Buy

Ask	3.72
Volume	312,272
Avg. Volume (20D)	2,942,067
Open	3.73
Previous Close	3.70
Day's Range	3.71 - 3.73
52-Week Range	3.38 - 7.63
Beta	1.02

About MNKD

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol MNKD

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for MNKD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

MannKind has released their quartely earnings on Aug 6, 2025:

Revenue of $76.53M misses estimates by $2.16M, with 5.72% YoY growth.

EPS of 0.05 misses estimates by -0.01, with 0.00% YoY growth.

Next Earnings Release

MannKind Corporation is scheduled to release its earnings on Nov 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

7 months ago

+8.73%

MannKind shares are trading higher after Wells Far... Unlock content with Pro Subscription

News

1 week ago · seekingalpha.com

MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript

MannKind Corporation (NASDAQ:MNKD ) Q2 2025 Earnings Call August 6, 2025 9:00 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.

1 week ago · seekingalpha.com

MannKind Corporation: A Post-Q2 Assessment

Today, we take another look at MannKind Corporation, which specializes in inhaled therapeutics for endocrine and orphan lung diseases, with a market cap of $1.15 billion. The company just reported sec...

1 week ago · zacks.com

MannKind (MNKD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimate...

1 week ago · zacks.com

MannKind (MNKD) Reports Break-Even Earnings for Q2

MannKind (MNKD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.04. This compares to earnings of $0.05 per share a year ago.

2 weeks ago · zacks.com

Analysts Estimate MannKind (MNKD) to Report a Decline in Earnings: What to Look Out for

MannKind (MNKD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago · seekingalpha.com

MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition

MannKind's stock decline is likely due to concerns over Tyvaso DPI competition from Liquidia, but I believe these fears are exaggerated. Tyvaso DPI provides MannKind with a stable revenue base, suppor...